Terms: = Leukemia AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715
959 results:
1. Genetic mutations and immune microenvironment: unveiling the connection to AML prognosis.
Hu Z; Yang Y; Li J; Hu Z
Hematology; 2024 Dec; 29(1):2346965. PubMed ID: 38687637
[TBL] [Abstract] [Full Text] [Related]
2. [Gene Profile and Clinical Significance of Concomitant Mutations in CN-AML Patients with
Zhu J; Kang YF; Gao Y; Wang HW; Hao ZH; Wang HW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):335-341. PubMed ID: 38660833
[TBL] [Abstract] [Full Text] [Related]
3. Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies.
Ip BBK; Wong ATC; Law JHY; Au CH; Ma SY; Chim JCS; Liang RHS; Leung AYH; Wan TSK; Ma ESK
Sci Rep; 2024 Mar; 14(1):6400. PubMed ID: 38493200
[TBL] [Abstract] [Full Text] [Related]
4. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
[TBL] [Abstract] [Full Text] [Related]
5. Clinical features and management of germline cebpa-mutated carriers.
Pan L; Li Y; Gao H; Lai X; Cai Y; Chen Z; Li X; Wang SY
Leuk Res; 2024 Mar; 138():107453. PubMed ID: 38442594
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical Significance of Genetic and Molecular Changes in Primary Myeloid Sarcoma].
Jiang YJ; Zhang CF; Wang HX; Zhao L; Zhang FF; Han XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):27-32. PubMed ID: 38387895
[TBL] [Abstract] [Full Text] [Related]
7. Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses.
Severens JF; Karakaslar EO; van der Reijden BA; Sánchez-López E; van den Berg RR; Halkes CJM; van Balen P; Veelken H; Reinders MJT; Griffioen M; van den Akker EB
Leukemia; 2024 Apr; 38(4):751-761. PubMed ID: 38360865
[TBL] [Abstract] [Full Text] [Related]
8. cebpa double mutations associated with ABO antigen weakness in hematologic diseases.
Choi SJ; Kim HK; Suh EJ; Kwon SS; Shin S; Lee ST; Kim S
Blood Adv; 2024 Mar; 8(6):1487-1493. PubMed ID: 38359363
[TBL] [Abstract] [Full Text] [Related]
9. Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
Zhang T; Zhang Y; Zhou M; Zhang Z; Bao X; Wen L; Feng Y; Li X; Zhai M; Liu X; Zeng Z; Wu X; Chen S
Br J Haematol; 2024 Apr; 204(4):1402-1413. PubMed ID: 38327115
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia.
Tarlock K; Gerbing RB; Ries RE; Smith JL; Leonti A; Huang BJ; Kirkey D; Robinson L; Peplinksi JH; Lange B; Cooper TM; Gamis AS; Kolb EA; Aplenc R; Pollard JA; Alonzo TA; Meshinchi S
Blood Adv; 2024 May; 8(9):2094-2103. PubMed ID: 38295280
[TBL] [Abstract] [Full Text] [Related]
11. [Suspicion of constitutional abnormality at diagnosis of childhood leukemia: Update of the leukemia committee of the French Society of Childhood Cancers].
Strullu M; Cousin E; de Montgolfier S; Fenwarth L; Gachard N; Arnoux I; Duployez N; Girard S; Guilmatre A; Lafage M; Loosveld M; Petit A; Perrin L; Vial Y; Saultier P
Bull Cancer; 2024 Mar; 111(3):291-309. PubMed ID: 38267311
[TBL] [Abstract] [Full Text] [Related]
12. Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with cebpa bZIP in-frame mutations.
Tien FM; Yao CY; Tsai XC; Lo MY; Chen CY; Lee WH; Lin CC; Kuo YY; Peng YL; Tseng MH; Wu YS; Liu MC; Lin LI; Chuang MK; Ko BS; Yao M; Tang JL; Chou WC; Hou HA; Tien HF
Blood Cancer J; 2024 Jan; 14(1):15. PubMed ID: 38253683
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic impact of cebpa mutational subgroups in adult AML.
Georgi JA; Stasik S; Kramer M; Meggendorfer M; Röllig C; Haferlach T; Valk P; Linch D; Herold T; Duployez N; Taube F; Middeke JM; Platzbecker U; Serve H; Baldus CD; Muller-Tidow C; Haferlach C; Koch S; Berdel WE; Woermann BJ; Krug U; Braess J; Hiddemann W; Spiekermann K; Boertjes EL; Hills RK; Burnett A; Ehninger G; Metzeler K; Rothenberg-Thurley M; Dufour A; Dombret H; Pautas C; Preudhomme C; Fenwarth L; Bornhäuser M; Gale R; Thiede C
Leukemia; 2024 Feb; 38(2):281-290. PubMed ID: 38228680
[TBL] [Abstract] [Full Text] [Related]
14. Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome.
Arai H; Matsui H; Chi S; Utsu Y; Masuda S; Aotsuka N; Minami Y
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203823
[TBL] [Abstract] [Full Text] [Related]
15. Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance.
Mishra R; Zokaei Nikoo M; Veeraballi S; Singh A
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203655
[TBL] [Abstract] [Full Text] [Related]
16. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with cebpa bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H
Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444
[TBL] [Abstract] [Full Text] [Related]
17. DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic leukemia: Focus on the Genes Involved.
Risinskaya N; Gladysheva M; Abdulpatakhov A; Chabaeva Y; Surimova V; Aleshina O; Yushkova A; Dubova O; Kapranov N; Galtseva I; Kulikov S; Obukhova T; Sudarikov A; Parovichnikova E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139431
[TBL] [Abstract] [Full Text] [Related]
18. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G; McCloskey J; Griffiths EA; Yee KWL; Zeidan AM; Al-Kali A; Deeg HJ; Patel PA; Sabloff M; Keating MM; Zhu N; Gabrail NY; Fazal S; Maly J; Odenike O; Kantarjian H; DeZern AE; O'Connell CL; Roboz GJ; Busque L; Buckstein R; Amin H; Randhawa J; Leber B; Shastri A; Dao KH; Oganesian A; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2024 Jan; 11(1):e15-e26. PubMed ID: 38135371
[TBL] [Abstract] [Full Text] [Related]
19. LILRB3 Modulates Acute Myeloid leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy.
Mai S; Hodges A; Chen HM; Zhang J; Wang YL; Liu Y; Nakatsu F; Wang X; Fang J; Xu Y; Davidov V; Kang K; Pingali SR; Ganguly S; Suzuki M; Konopleva M; Prinzing B; Zu Y; Gottschalk S; Lu Y; Chen SH; Pan PY
Cancer Res; 2023 Dec; 83(24):4047-4062. PubMed ID: 38098451
[TBL] [Abstract] [Full Text] [Related]
20. Assessment of 2022 European leukemiaNet risk classification system in real-world cohort from China.
Chen E; Jiao C; Yu J; Gong Y; Jin D; Ma X; Cui J; Wu Z; Zhou J; Wang H; Su B; Ge J
Cancer Med; 2023 Dec; 12(24):21615-21626. PubMed ID: 38098254
[TBL] [Abstract] [Full Text] [Related]
[Next]
